FOLH1 and prostate cancer: Meta-analyses have confirmed that 68Ga-PSMA PET/CT had dominant advantages in detecting the recurrence and staging of prostate cancer (26, 27), and the pooled sensitivity and specificity for detecting prostate cancer recurrence was 70% and 97%, as well as the pooled sensitivity and specificity of prostate cancer staging/restaging studies was 92% and 94%, respectively.